Navigation Links
Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
Date:2/19/2013

CARLSBAD, Calif., Feb. 19, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 2/3 clinical study for ISIS-TTRRx.  ISIS-TTRRx is an antisense drug in development with GlaxoSmithKline (GSK) for the treatment of transthyretin (TTR) amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.  Isis and GSK recently amended the clinical development plan and financial terms relating to ISIS-TTRRx to support this registration-directed Phase 2/3 clinical study on ISIS-TTRRx.

"TTR amyloidosis is a severe and rare genetic disease that leads to death.  TTR amyloidosis affects approximately 50,000 patients worldwide and current treatments are limited.  Patients with familial amyloid polyneuropathy, or FAP, experience TTR build up in their peripheral nerves and experience the loss of motor functions, such as walking," said Merrill D. Benson , M.D., Professor of Medical Genetics at Indiana University.  "By inhibiting the production of TTR protein, ISIS-TTRRx could offer an alternative approach to treating patients with FAP.  Furthermore, a drug that can reduce TTR levels could potentially slow or arrest progression of this terrible disease."

The Phase 2/3 study of ISIS-TTRRx is a randomized, double-blinded, placebo-controlled, international study designed to support an application for marketing approval of ISIS-TTRRx in patients with FAP.  The fifteen month study will enroll approximately 200 patients randomized 2:1 to receive 300 mg/week of ISIS-TTRRx or placebo and will measure the effects of ISI
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2. Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
3. NW Bio Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe
4. Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
5. RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
6. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
7. Matrixx Initiatives Withdraws Acquisition Offer for ProPhase Labs
8. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
9. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
10. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
11. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015 WuXi PharmaTech (Cayman) Inc. ... capability and technology platform company serving the pharmaceutical, biotechnology, ... the United States, today announced its financial results for ... Fourth-Quarter 2014 Highlights , Net Revenues Increased ... Laboratory Services Net Revenues Grew 17.7% Year Over Year ...
(Date:3/5/2015)... Germany , March 5, 2015 ... today announced that the foundation has made a ... CureVac, a leading clinical-stage biopharmaceutical company specializing in ... the foundation will also provide separate funding for ... CureVac,s proprietary messenger RNA (mRNA) platform. In addition, ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. ... its second quarter ended January 31, 2015 on Thursday, March ... to discuss the results at 11:00 AM ET. ... approximately 5 to 10 minutes before the beginning of the ... of the call will be available from Thursday, March 12, ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... March 05, 2015 Today, Earth ... running on 100% pollution-free electricity through a partnership ... , As an Arcadia Power Clean Energy Partner, ... Green Power Partnership requirements, joining national brands such ... purchase clean energy. Earth Source Organics joins a ...
(Date:3/5/2015)... March 05, 2015 The Journal ... released a special issue devoted entirely ... of PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with ... autoimmune reaction triggered by infections such as strep ... in inflammation of the child's brain. This inflammation ...
(Date:3/5/2015)... Think it’s tough to get kids to eat their ... brush their teeth. That’s a finding from a new survey ... in conjunction with National Parenting Month in March. , ... brush their teeth is one of the most challenging things ... getting children to eat vegetables regularly (42 percent) or getting ...
(Date:3/5/2015)... Raton, Florida (PRWEB) March 05, 2015 ... testing organization which provides vascular, echocardiogram and ... M.D., F.A.C.C. as the Chief Medical Officer. Dr. Artel ... lines, the development of the WimbledonMED program and the ... “I’ve been passionate about working with Wimbledon Health Partners ...
Breaking Medicine News(10 mins):Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3
... Neurologic & Orthopedic Hospital of Chicago,s Michael Vender, M.D., offers tips to ... a downloadable pdf and also via mail with an attachable sticker. ... ... snow blowers to shovel out their driveways this winter, the Neurologic & ...
... not just the geological kind but the mental kind ... can experience post-traumatic stress disorder, depression and anxiety. ... Armenia killed 17,000 people and destroyed nearly half the ... of its kind, UCLA researchers studying survivors of that ...
... out of the University of Pittsburgh indicates that ... have an impact on how much they walk. ... Therapy (December 2008), the scientific journal of ... "The purpose of this cross-sectional study was to ...
... risk, researchers say , , FRIDAY, Dec. 19 (HealthDay News) ... type 1 diabetes have insufficient levels of vitamin D, ... , A deficit in vitamin D can lead to ... type 1 diabetes. While vitamin D is usually gotten ...
... The increase, while modest, was significant, study finds , , ... of unhealthy snacks in elementary schools led to a ... a new study found. , The roughly 3 percent ... in schools that restricted the availability of snacks was ...
... decreases risk of death, study finds, , , FRIDAY, Dec. 19 (HealthDay ... of caregiving, but a new study suggests there may be a ... age -- a decreased risk of death. , "We found that ... week caregiving lived longer and reduced their risk of dying by ...
Cached Medicine News:Health News:Complimentary Pamphlet on Avoiding Snow Blower Injuries Offered by Chicago Hospital 2Health News:Vulnerability to post-traumatic stress disorder runs in families, study shows 2Health News:Most Kids With Type 1 Diabetes Lack Vitamin D 2Health News:Most Kids With Type 1 Diabetes Lack Vitamin D 3Health News:Limiting School Snacks Boosts Fruit, Veggie Consumption 2Health News:Limiting School Snacks Boosts Fruit, Veggie Consumption 3Health News:Caregiving May Lengthen Life 2Health News:Caregiving May Lengthen Life 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: